BNF presentation directory

Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.

Chapter

Reset

Presentation	Product	Chemical substance	Chapter	Items dispensed
C-View Post-Op dressing 8.5cm x 9.5cm 20030100377	C-View Post-Op dressing 8.5cm x 9.5cm	Wound Management & Other Dressings	Dressings	No data available
C1-esterase inhibitor 1,500unit inj vials 0304030F0AAAEAE	C1-Esterase inhibitor	C1-Esterase inhibitor	Respiratory System	No data available
Cabaser 4mg tablets 0409010U0BBACAC	Cabaser	Cabergoline	Central Nervous System	No data available
Cabergoline 4mg tablets 0409010U0AAACAC	Cabergoline (Parkinsonism)	Cabergoline	Central Nervous System	No data available
Cabometyx 20mg tablets 0801050BRBCAAAC	Cabometyx	Cabozantinib	Malignant Disease and Immunosuppression	No data available
Cabometyx 40mg tablets 0801050BRBCABAD	Cabometyx	Cabozantinib	Malignant Disease and Immunosuppression	No data available
Cabometyx 60mg tablets 0801050BRBCACAE	Cabometyx	Cabozantinib	Malignant Disease and Immunosuppression	No data available
Cabotegravir 30mg tablets 0503010AWAAAAAA	Cabotegravir	Cabotegravir	Infections	No data available
Cabotegravir 600mg/3ml prolonged-release inj vials 0503010AWAAABAB	Cabotegravir	Cabotegravir	Infections	No data available
Cabozantinib 20mg capsules 0801050BRAAAAAA	Cabozantinib	Cabozantinib	Malignant Disease and Immunosuppression	No data available
Cabozantinib 20mg capsules and Cabozantinib 80mg capsules 0801050BRAAABAB	Cabozantinib	Cabozantinib	Malignant Disease and Immunosuppression	No data available
Cabozantinib 20mg tablets 0801050BRAAACAC	Cabozantinib	Cabozantinib	Malignant Disease and Immunosuppression	No data available
Cabozantinib 40mg tablets 0801050BRAAADAD	Cabozantinib	Cabozantinib	Malignant Disease and Immunosuppression	No data available
Cabozantinib 60mg tablets 0801050BRAAAEAE	Cabozantinib	Cabozantinib	Malignant Disease and Immunosuppression	No data available
Cabren 2.5mg modified-release tablets 0206020F0BDABAD	Cabren	Felodipine	Cardiovascular System	No data available
Cabren 5mg modified-release tablets 0206020F0BDAAAB	Cabren	Felodipine	Cardiovascular System	No data available
Cadaff XL 80mg tablets 0212000M0BHAAAD	Cadaff XL	Fluvastatin sodium	Cardiovascular System	No data available
Cade oil 12.5% in Emulsifying ointment 190605000AACECE	Generic compound preparation BNF 1906050	Other oil preparations	Other Drugs and Preparations	No data available
Cade oil 12% / Salicylic acid 4% in Emulsifying ointment 190605000AACDCD	Generic compound preparation BNF 1906050	Other oil preparations	Other Drugs and Preparations	No data available
Cade oil 6%/Salicylic acid 3%/Sulfur 3% in Emulsifying oint 1306010T0AABMBM	Sulfur (Topical)	Sulfur	Skin	No data available
Cade oil liquid 190605000AAAEAE	Generic compound preparation BNF 1906050	Other oil preparations	Other Drugs and Preparations	No data available
Caelyx pegylated liposomal 20mg/10ml concentrate for inf 0801020K0BDAAAF	Caelyx	Doxorubicin hydrochloride	Malignant Disease and Immunosuppression	No data available
Caelyx pegylated liposomal 50mg/25ml concentrate for inf 0801020K0BDABAG	Caelyx	Doxorubicin hydrochloride	Malignant Disease and Immunosuppression	No data available
Cafergot suppositories 0407041F0BFAAAH	Cafergot	Ergotamine tartrate	Central Nervous System	No data available
Cafergot tablets 0407041F0BFABAM	Cafergot	Ergotamine tartrate	Central Nervous System	No data available

Why monitor BNF codes?

Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.

Track cost pressure

Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.

Understand demand drivers

Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.